GlassScriptPhysician profile
Arian Majko
NPI 1578902755
$2,189.10
in general payments reported to CMS, 2019-2025
34 companies · $69.05 in 2025
The $69.05 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.58 · 2020: $16.61 · 2021: $20.00 · 2022: $900 · 2023: $1,102 · 2024: $22.80 · 2025: $69.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,043.80 |
| Education | $149.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $248.26 | 2022-2023 | Rezlidhia, Tavalisse |
| Merck Sharp & Dohme LLC | $180.85 | 2023 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $178.32 | 2020-2025 | Darzalex, Tecvayli, Talvey |
| Astellas Pharma US INC | $172.40 | 2022-2023 | Padcev |
| Seagen INC. | $153.15 | 2022-2023 | Tukysa |
| Genzyme Corporation | $141.82 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $125.97 | 2022-2023 | Opdivo, Opdualag |
| Pfizer INC. | $84.16 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $78.77 | 2022-2023 | |
| Lilly USA, LLC | $69.85 | 2022-2023 | Verzenio |
| Astrazeneca Pharmaceuticals LP | $69.68 | 2022-2023 | Imfinzi |
| Pharmacyclics LLC, An Abbvie Company | $68.28 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.38 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $53.45 | 2022-2023 | |
| Celgene Corporation | $47.63 | 2023-2025 | Reblozyl, Breyanzi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $42.86 | 2023 | Krazati |
| Gilead Sciences, INC. | $41.72 | 2023 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $39.59 | 2022-2023 | Ninlaro |
| Eisai INC. | $34.98 | 2022-2023 | |
| Daiichi Sankyo INC. | $28.95 | 2022 | |
| Beigene USA, INC. | $27.17 | 2023 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $24.76 | 2022 | |
| Abbvie INC. | $23.16 | 2022 | |
| Adaptive Biotechnologies Corporation | $22.80 | 2024 | Clonoseq |
| Exelixis INC. | $19.74 | 2022 | |
| Myriad Genetic Laboratories, INC. | $19.30 | 2023 | Myrisk |
| Array Biopharma INC | $17.03 | 2023 | Lorbrena, Xalkori, Mektovi |
| Pharmaessentia USA Corporation | $17.02 | 2022 | |
| Incyte Corporation | $16.95 | 2023 | Pemazyre, Monjuvi |
| Kite Pharma, INC. | $16.69 | 2023 | |
| Sobi, INC | $16.48 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.60 | 2023 | Libtayo |
| Clovis Oncology, INC. | $13.76 | 2019 | |
| Amgen INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arian Majko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.